PFG
BIB icon

Piershale Financial Group’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Piershale Financial Group’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-28
Closed -$2K – 109
2015
Q1 		$2K Buy
+28
New +$2.08K ﹤0.01% 114
2014
Q1 		– Sell
-84
Closed -$3K – 144
2013
Q4 		$3K Buy
+84
New +$2.81K ﹤0.01% 87

Other funds holding BIB

AP
Advisors Preferred Rockville, Maryland $679M AUM 22.19% 1-Year Est. Return
VCAM
Valentine Capital Asset Management Danville, California $89.6M AUM 0.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Piershale Financial Group's BIB Position: Q2 2015 in Review

Piershale Financial Group sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2015, closing a stake of 28 shares — an estimated $2K sold.

Piershale Financial Group first reported a position in BIB in Q4 2013 and held it in 2 quarters. The position peaked at $3K in Q4 2013. 27 funds tracked by Wall St. Rank hold BIB as of Q2 2015.

  • Piershale Financial Group reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2015 after selling out during the quarter.
  • Piershale Financial Group sold 28 ProShares Ultra NASDAQ Biotechnology shares in Q2 2015, an estimated $2K.
  • Piershale Financial Group first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2013 and held it in 2 quarters.
  • Piershale Financial Group's ProShares Ultra NASDAQ Biotechnology position peaked at $3K in Q4 2013.
  • 27 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2015.

Based on Piershale Financial Group's 13F filing for Q2 2015, filed 14 Jul 2015.